Leading Companies - Middle East and Asia Pacific Cell and Gene Therapy Industry

In June 2017, Horama S.A. a biotechnology company announced that U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to HORARLBP1. A gene replacement therapy Moreover, HORARLBP1 is developed for the treatment of retinitis punctata albescens and retinitis pigmentosa caused by mutations in the RLBP1 gene.

Middle East and Asia Pacific Cell And Gene Therapy Market

is estimated to be valued at US$ 2,616.8 million in 2021 and is expected to exhibit a CAGR of 17.3% over the forecast period (2021-2028).

Key Competitors in the Middle East and Asia Pacific Cell and Gene Therapy Industry:

Novartis International AG:

1. Innovative Medicines and Sandoz are two business sectors under which Novartis develops and produces healthcare goods. company Innovative pharmaceuticals sector, which includes international business franchises in oncology, ophthalmology, neurology, immunology, respiratory, cardio-metabolic, and established pharmaceuticals, accounts for the vast bulk of company revenue. Founded in 1996. Novartis successfully acquires The Medicines Company, adding the investigational cholesterol-lowering drug inclisiran, which may be a first-in-class treatment. 

Pfizer, Inc.:

2. The Company used to sell a wide variety of chemicals and healthcare items, but today the majority of its sales come from prescription medications and vaccinations. Prevnar 13, an anti-pneumococcal vaccination, Ibrance, Eliquis, and Xeljanz are some of the best-selling medications.  Established in 1848. Headquarters are located in New York, USA. Truveta Announces Strategic Partnership with Pfizer to Quicken Real-Time Safety Insights

Sanofi S.A.:

3.   Created in 1994. Therapeutics created and distributed with patients' needs in mind. The business sells consumer healthcare items, vaccines for humans, animal health goods, and drugs for diabetes and cancer. Headquartered in France, Paris.

Amgen, Inc.:

4. Amgen is a pioneer in biotechnology-based human medicines with a track record in supportive care for cancer patients and renal disease. Founded 1980. United States, Oaks, California 91320-1799. Acquisition Contains TAVNEOS® (avacopan), a First-in-Class Drug for People With Serious Autoimmune Disease.

Tavneos Strengthens Amgen's Decades of Nephrology and Inflammation Leadership.

Regeneron Pharmaceuticals, Inc., F:

5. Established in 1988, with headquarters in Tarrytown, New York, Regeneron Pharmaceuticals finds, creates, and sells medicines to treat inflammation, cancer, cardiovascular disease, and eye disorders.

Hoffmann-La Roche AG:

6. Tasmar's rights to production, marketing, and distribution in the United States and a few other non-European Union areas. Parkinson's illness is managed with the medication tasmar. Roche plans to purchase the TIB Molbiol Group, with a closing anticipated for the fourth quarter of 2021.

*Definition:

A process called gene therapy alters a person's genes to treat or eradicate disease.